News >

Cabozantinib RCC Benefit Highlighted as Frontline Approval Approaches

Gina Columbus @ginacolumbusonc
Published: Wednesday, Nov 15, 2017

Michael R. Harrison, MD

Michael R. Harrison, MD
The multikinase inhibitor cabozantinib (Cabometyx) remains to be the sole oral drug to meet 3 clinical trial endpoints of progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in patients with advanced renal cell carcinoma (RCC), Michael R. Harrison, MD, noted in a presentation at the 35th Annual CFS® meeting.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x